Dopamine D1 receptor alleviates doxorubicin-induced cardiac injury by inhibiting NLRP3 inflammasome
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 561, 7-13
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
This publication has 29 references indexed in Scilit:
- NLRP3 Deficiency Reduces Macrophage Interleukin-10 Production and Enhances the Susceptibility to Doxorubicin-induced CardiotoxicityScientific Reports, 2016
- Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the MouseJournal of Cardiovascular Pharmacology, 2015
- Cardiotoxicity of anticancer treatmentsNature Reviews Cardiology, 2015
- Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 InflammasomeCell, 2015
- Role of dopamine D2 receptors in ischemia/reperfusion induced apoptosis of cultured neonatal rat cardiomyocytesJournal of Biomedical Science, 2011
- Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicityEuropean Journal of Pharmacology, 2010
- Dopamine D1-like receptor activation depolarizes medium spiny neurons of the mouse nucleus accumbens by inhibiting inwardly rectifying K+ currents through a cAMP-dependent protein kinase A-independent mechanismNeuroscience, 2010
- Cocaine-induced alterations in dopamine receptor signaling: Implications for reinforcement and reinstatementPharmacology & Therapeutics, 2005
- Localization of the Dopamine D1Receptor Protein in the Human Heart and KidneyHypertension, 1997
- Expression of the Subtype 1A Dopamine Receptor in the Rat HeartHypertension, 1996